Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Atrium Therapeutics, Inc.NASDAQ: RNA

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures of -$2.1M in Q1 FY2026

Q1 FY2026 capital expenditures was -$2.1M.

Context

  • Capital expenditures amounted to 7.8% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.1M+138.7% QoQ
Last fiscal yearDec 2025
-$1.45M— YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.45M) USD
Year-over-year change
—

Capital Expenditures vs competitors

How RNA compares with its peers on the latest reported figures

No competitor Capital Expenditures figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.